Literature DB >> 8527219

The hypobetalipoproteinemias.

G Schonfeld1.   

Abstract

The fifth- and ninety-fifth-percentile concentrations of low-density lipoprotein (LDL) cholesterol in most Western populations are approximately 90 and 200 mg/dl, respectively. Persons with LDL cholesterol levels equal to or less than the fifth percentile are defined as having hypobetalipoproteinemia. Epidemiologic studies show that such individuals have lower-than-average risk for atherosclerotic cardiovascular disease but higher risk for a variety of cancers, pulmonary, and gastrointestinal diseases than persons with higher levels of cholesterol. The reasons for this are not known, nor are the causes of most cases of hypobetalipoproteinemia. However, in some well-studied kindreds the hypobetalipoproteinemia phenotype is inherited as an autosomal dominant trait. Heterozygotes in such kindreds are usually healthy and have no difficulty absorbing dietary fat. In most kindreds, the molecular variants responsible for the hypobetalipoproteinemia are unknown, but a subset of kindreds have strong genetic linkages between the low-cholesterol phenotype and truncation-producing mutations of the apolipoprotein (apo) B-100 gene. The truncations of apoB are named according to a centile nomenclature. The full-length 4536-amino acid protein is called apoB-100, and the 25 truncations identified to date have been named apoB-2 to apoB-89. The mutations introduce premature termination codons resulting from frameshift-producing base additions or deletions. The mutations produce slowed rates of secretion of the truncated apoBs relative to the apoB-100s present in the heterozygotes. In addition, the apoB-100 molecules of the heterozygotes are also secreted at rates slower than those observed in closely matched normolipidemic controls. These physiologic results account for the hypobetalipoproteinemia of these subjects. The response of the plasma lipoproteins of heterozygotes to the manipulation of various dietary components remains to be determined. Additional low-cholesterol syndromes are autosomal recessive forms of hypobetalipoproteinemia, chylomicron retention disease, and abetalipoproteinemia. The molecular causes of the first two are unknown. Abetalipoproteinemia is an autosomal recessive condition resulting from mutations of the microsomal triglyceride transfer protein. All three conditions are characterized by vanishingly small concentrations of LDL, dietary fat malabsorption, and failure to thrive in infancy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8527219     DOI: 10.1146/annurev.nu.15.070195.000323

Source DB:  PubMed          Journal:  Annu Rev Nutr        ISSN: 0199-9885            Impact factor:   11.848


  11 in total

1.  Unusual presentation of three siblings with familial heterozygous hypobetalipoproteinaemia.

Authors:  V Kairamkonda; M Dalzell
Journal:  Eur J Pediatr       Date:  2003-01-11       Impact factor: 3.183

2.  PCSK9 - A New and Potent Approach to Lowering Cholesterol.

Authors:  Thomas F Whayne
Journal:  Oman Med J       Date:  2013-05

Review 3.  Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma.

Authors:  A Lonardo; P Tarugi; G Ballarini; A Bagni
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

4.  Truncated apo B-70.5-containing lipoproteins bind to megalin but not the LDL receptor.

Authors:  Z Chen; J E Saffitz; M A Latour; G Schonfeld
Journal:  J Clin Invest       Date:  1999-05-15       Impact factor: 14.808

5.  Linkage of a gene for familial hypobetalipoproteinemia to chromosome 3p21.1-22.

Authors:  B Yuan; R Neuman; S H Duan; J L Weber; P Y Kwok; N L Saccone; J S Wu; K Y Liu; G Schonfeld
Journal:  Am J Hum Genet       Date:  2000-04-10       Impact factor: 11.025

Review 6.  Problems and possible solutions for therapy with statins.

Authors:  Thomas F Whayne
Journal:  Int J Angiol       Date:  2013-06

Review 7.  Is There an Ideal Low-Density Lipoprotein Cholesterol Level? Confusion regarding Lipid Guidelines, Low-Density Lipoprotein Cholesterol Targets, and Medical Management.

Authors:  Thomas F Whayne
Journal:  Int J Angiol       Date:  2016-12-12

8.  Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.

Authors:  Maartje E Visser; Fatima Akdim; Diane L Tribble; Aart J Nederveen; T Jesse Kwoh; John J P Kastelein; Mieke D Trip; Erik S G Stroes
Journal:  J Lipid Res       Date:  2009-12-14       Impact factor: 5.922

Review 9.  Recent advances in vitamin E metabolism and deficiency.

Authors:  Ephrem Eggermont
Journal:  Eur J Pediatr       Date:  2006-02-21       Impact factor: 3.183

10.  Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes.

Authors:  David B Rozema; David L Lewis; Darren H Wakefield; So C Wong; Jason J Klein; Paula L Roesch; Stephanie L Bertin; Tom W Reppen; Qili Chu; Andrei V Blokhin; James E Hagstrom; Jon A Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.